Table 1.
Patient characteristics
| Variable | All GLP-1 RA (n = 932) | Dulaglutide (n = 612) | Liraglutide (n = 271) |
|---|---|---|---|
| Age, years | 63.8 (13.3) | 64.6 (13.3) | 63.4 (12.8) |
| Age category, years, n (%) | |||
| 18–29 | 9 (1.0) | 5 (0.8) | 3 (1.1) |
| 30–39 | 32 (3.4) | 17 (2.8) | 11 (4.1) |
| 40–49 | 110 (11.8) | 67 (10.9) | 29 (10.7) |
| 50–59 | 168 (18.0) | 112 (18.3) | 44 (16.2) |
| 60–69 | 275 (29.5) | 177 (28.9) | 90 (33.2) |
| 70–79 | 226 (24.2) | 142 (23.2) | 74 (27.3) |
| ≥ 80 | 112 (12.0) | 92 (15.0) | 20 (7.4) |
| Male, n (%) | 522 (56.0) | 329 (53.8) | 171 (63.1) |
| Body weight, kga | 71.7 (17.9) | 71.1 (17.6) | 71.6 (17.5) |
| BMI, kg/m2b | 27.4 (5.4) | 27.5 (5.4) | 26.8 (5.3) |
| Duration of diabetes, yearsc | 16.1 (9.6) | 16.2 (9.6) | 16.5 (9.5) |
| Comorbidities, n (%) | |||
| Obesity | 547 (58.7) | 367 (60.0) | 140 (51.7) |
| Hypertension | 510 (54.7) | 326 (53.3) | 163 (60.1) |
| Dyslipidemia | 485 (52.0) | 317 (51.8) | 144 (53.1) |
| Retinopathy | 105 (11.3) | 55 (9.0) | 42 (15.5) |
| Nephropathy | 95 (10.2) | 76 (12.4) | 15 (5.5) |
| Myocardial infarction | 2 (0.2) | 1 (0.2) | 1 (0.4) |
| Cerebral infarction | 2 (0.2) | 1 (0.2) | 1 (0.4) |
| Lower extremity amputations | 0 | 0 | 0 |
Data are mean (standard deviation) unless otherwise stated
BMI body mass index, GLP-1 RA glucagon-like peptide-1 receptor agonist
aAll GLP-1 RA n = 844; dulaglutide n = 554; liraglutide n = 243
bAll GLP-1 RA n = 831; dulaglutide n = 545; liraglutide n = 239
cAll GLP-1 RA n = 888; dulaglutide n = 584; liraglutide n = 256